Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial Guidance

2 years ago

Scott Leffler Myriad Genetics, Inc., a leader in genetic testing and precision medicine, today announced the appointment of Scott Leffler…

Apnimed Announces First Patient Dosed in SynAIRgy, the Second Phase 3 Clinical Study of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea

2 years ago

-- SynAIRgy Compares AD109 to Placebo Over 6 Months in People with OSA who Are Intolerant of or Refuse Positive…

BioAdaptives, Inc. to Form New Division, AI BodyShape Lab, to Promote Adult Fitness and Weight Management

2 years ago

BioAdaptives, Inc. BioAdaptives’ AI-based Fit Your Outfit app LAS VEGAS, NV, Dec. 21, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire –…

IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial

2 years ago

NEW YORK, Dec. 21, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating…

DMK Pharmaceuticals Regains Full Rights to Commercialize ZIMHI

2 years ago

Company seeking commercialization partnerships in the United States, Canada, and Europe to expand revenue generationSAN DIEGO, Dec. 21, 2023 (GLOBE NEWSWIRE)…

SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas

2 years ago

- SLS009 Demonstrated Promising Efficacy in Phase 1 Study with 36.4% Clinical Response (ORR) in r/r Peripheral T-cell Lymphomas (PTCL);…

Microbix Reports Results for Q4 & Full-Year Fiscal 2023

2 years ago

Full-Year Sales of $16.5 million and Net Loss of $0.04 millionMISSISSAUGA, Ontario, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems…

ITM to Present at the 42nd Annual J.P. Morgan Healthcare Conference

2 years ago

Garching / Munich, Germany, December 21, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today…

BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer

2 years ago

Designation is based on Phase 1/2 safety and efficacy data in patients with Human Epidermal Growth Factor Receptor 2 (“HER2”)-expressing…

Curevo Vaccine to present at the 42nd Annual J.P. Morgan Healthcare Conference

2 years ago

SEATTLE, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the…